Summary of Study ST002468
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001594. The data can be accessed directly via it's Project DOI: 10.21228/M8NQ69 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002468 |
| Study Title | First approach on the use of samples from fecal occult blood screening kits for metabolomic analysis. Application in colorectal cancer population. |
| Study Summary | Cancer is the most common disease around the world and colorectal cancer is the second most common cancer. The early diagnosis of colorectal cancer is difficult and relies on invasive diag-nostic tools such as colonoscopy and tissue biopsy. Other non-invasive techniques such as fecal occult blood screening test (FOBT) are less sensitive and accurate. The advantage of FOBT together with high throughput technology such as metabolomics could provide the advantages of non-invasive tool and the effectiveness of detecting novel colorectal cancer markers. In this way, this work focuses on the novelty of using FOBT as samples to perform metabolomics analysis and its application on colorectal cancer population. |
| Institute | CIC bioGUNE - Centro de Investigación Cooperativa en Biociencias |
| Last Name | Alboniga |
| First Name | Oihane |
| Address | Bizkaia Technology Park, Bld.800, Derio, Bizkaia, 48160, Spain |
| oalboniga@cicbiogun.es | |
| Phone | +34 944061317 |
| Submit Date | 2022-12-09 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-02-22 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002551 |
| Collection Summary: | Samples were collected from the Biodonostia Health Research Institute. The inclusion criteria were asymptomatic individuals with intermediate risk. That is, individuals from 50 to 69 years that do not have clinical symptoms, and patients that do not have any family history or other factor associated with colorectal cancer. The study was conducted according to the clinical and ethical principals of the Spanish Government and the Declaration of Helsinki and it was approved by the Ethics Committee for Clinical Research of Euskadi (PI2013073). Informed consent was obtained from each individual. Patients and control individuals self-collected a fecal sample from one bowel movement without specific diet or medication restrictions at home the week before a colonoscopy was performed. |
| Sample Type: | Feces |
